Obesity, inflammation, and insulin resistance

Harvard University, Cambridge, Massachusetts, United States
Gastroenterology (Impact Factor: 13.93). 06/2007; 132(6):2169-80. DOI: 10.1053/j.gastro.2007.03.059
Source: PubMed

ABSTRACT Weight gain and obesity are major risk factors for conditions and diseases ranging from insulin resistance and type 2 diabetes mellitus to atherosclerosis and the sequelae of nonalcoholic fatty liver disease. A chronic, subacute state of inflammation often accompanies the accumulation of excess lipid in adipose tissue and liver (hepatic steatosis), evidenced by changes in both inflammatory cells and biochemical markers of inflammation. These changes can be seen in the involved tissues and systemically, in terms of elevated circulating levels of inflammatory markers. The link between obesity and inflammation has therefore raised the important question of whether obesity-induced inflammation plays a pathogenic role in the development and progression of these disorders. We review the rapidly expanding body of animal and clinical data that support potential roles for inflammation in the pathogenesis of insulin resistance and type 2 diabetes mellitus.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Cathepsins are a diverse group of proteases that are increasingly being recognized for their role in various disease states. The focus of this article is to review the data regarding the activity of cathepsin K and cathepsin S in adipocyte differentiation and function as well as glucose metabolism. Data from animal and human studies have shown up-regulation of cathepsin K expression in white adipose tissue of overweight/obese mice and humans. Cathepsin K appears to affect adipocyte differentiation as well as weight gain. Data from studies using cathepsin K blocking agents suggest that by blocking cathepsin K, there is reduction in adipocyte differentiation and weight gain. Cathepsin K also may play a role in glucose metabolism with higher cathepsin K levels being associated with insulin resistance. Cathepsin S is also overexpressed in adipose tissue of overweight/obese subjects. Both murine and human models have been studied to further investigate its role in adipocytes and obesity. Cathepsin S appears to be involved in glucose dysregulation as well as pathogenesis of diabetes mellitus. Further studies are necessary to better characterize the role of cathepsin K and S and to examine whether there is potential for targeted therapy for prevention and treatment of obesity as well as diabetes mellitus.
    Clinical Reviews in Bone and Mineral Metabolism 01/2015; DOI:10.1007/s12018-015-9177-x
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity leads to adipose tissue inflammation that is characterized by increased release of proinflammatory molecules and the recruitment of activated immune cells. Although macrophages are present in the highest number among the immune cells in obese adipose tissue, not much is known about their direct interaction with adipocytes. We have introduced an ex vivo experimental system to characterize the cellular interactions and the profile of secreted cytokines in cocultures of macrophages and human adipocytes differentiated from either mesenchymal stem cells or a preadipocyte cell line. As observed by time-lapse microscopy, flow, and laser-scanning cytometry, macrophages phagocytosed bites of adipocytes (trogocytosis), which led to their de novo, phagocytosis and NF-κB-dependent synthesis, then release of interleukin (IL)-6 and monocyte chemoattractant protein (MCP)-1. IL-6 secretion was not accompanied by secretion of other proinflammatory cytokines, such as tumor necrosis factor (TNF)-α and IL-8, except MCP-1. LPS-induced release of TNF-α, IL-8 and MCP-1 was decreased in the presence of the differentiated adipocytes but the IL-6 level did not subside suggesting that phagocytosis-dependent IL-6 secretion may have significant regulatory function in the inflamed adipose tissue.
    Cell Death & Disease 01/2015; 6:e1613. DOI:10.1038/cddis.2014.579 · 5.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Insulin resistance (IR) is a general phenomenon of many physiological states, disease states, and diseases. IR has been described in diabetes mellitus, obesity, infection, sepsis, trauma, painful states such as postoperative pain and migraine, schizophrenia, major depression, chronic mental stress, and others. In arthritis, abnormalities of glucose homeostasis were described in 1920; and in 1950 combined glucose and insulin tests unmistakably demonstrated IR. The phenomenon is now described in rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, polymyalgia rheumatica, and others. In chronic inflammatory diseases, cytokine-neutralizing strategies normalize insulin sensitivity. This paper delineates that IR is either based on inflammatory factors (activation of the immune/ repair system) or on the brain (mental activation via stress axes). Due to the selfishness of the immune system and the selfishness of the brain, both can induce IR independent of each other. Consequently, the immune system can block the brain (for example, by sickness behavior) and the brain can block the immune system (for example, stress-induced immune system alterations). Based on considerations of evolutionary medicine, it is discussed that obesity per se is not a disease. Obesity-related IR depends on provoking factors from either the immune system or the brain. Chronic inflammation and/or stress axis activation are thus needed for obesity-related IR. Due to redundant pathways in stimulating IR, a simple one factor-neutralizing strategy might help in chronic inflammatory diseases (inflammation is the key), but not in obesity-related IR. The new considerations towards IR are interrelated to the published theories of IR (thrifty genotype, thrifty phenotype, and others).
    Arthritis Research & Therapy 01/2014; 16 Suppl 2:S4. DOI:10.1186/ar4688 · 4.12 Impact Factor

Full-text (2 Sources)

Available from
Jan 23, 2015